• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

    1/2/24 1:35:24 PM ET
    $ADTX
    $AHG
    $ALLO
    $AMPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate
    Real Estate
    Get the next $ADTX alert in real time by email

    Shares of Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) rose sharply during Tuesday’s session after the company released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs).

    Longboard Pharmaceuticals shares jumped 199.7% to $18.07 on Tuesday.

    Here are some other stocks moving in today's mid-day session.

    Gainers

    • Akso Health Group (NASDAQ:AHG) surged 85% to $1.2946.
    • Polished.com Inc. (NYSE:POL) gained 45% to $8.77.
    • Dogness (International) Corporation (NASDAQ:DOGZ) jumped 40% to $7.42.
    • Cue Health Inc. (NASDAQ:HLTH) gained 36.8% to $0.2224 after falling 42% on Friday.
    • Voyager Therapeutics, Inc. (NASDAQ:VYGR) surged 34% to $11.38 after the company announced a strategic collaboration and capsid license agreement with Novartis to advance potential gene therapies for Huntington's disease and spinal muscular atrophy.
    • RiskOn International, Inc. (NASDAQ:ROI) shares climbed 33.5% to $0.4450 after gaining around 17% on Friday. RiskOn International recently said it expects to announce its new generative AI platform and unveil a principal technology partner on Jan. 3.
    • Soligenix, Inc. (NASDAQ:SNGX) shares gained 33.4% to $1.01. Soligenix announced publication demonstrating complete protection against filovirus disease in nonhuman primate models of ebola and marburg viruses.
    • SenesTech, Inc. (NASDAQ:SNES) gained 22.2% to $1.56. SenesTech announced the expansion of its distribution agreement with Pesterminators Pvt Ltd to include the deployment of EvolveTM.
    • Brooge Energy Limited (NASDAQ:BROG) jumped 17.1% to $4.31. Brooge Energy recently announced that it reached a settlement with the SEC where it agreed to pay a $5 million penalty and cease any future violations.
    • Lyell Immunopharma, Inc. (NASDAQ:LYEL) gained 16.9% to $2.26.
    • Wheels Up Experience Inc. (NYSE:UP) surged 16.9% to $4.01.
    • BTCS Inc. (NASDAQ:BTCS) shares rose 14.1% to $1.8593 amid strength in Bitcoin.
    • Allogene Therapeutics, Inc. (NASDAQ:ALLO) gained 12% to $3.59.
    • Precigen, Inc. (NASDAQ:PGEN) rose 11.9% to $1.50.
    • Argo Blockchain plc (NASDAQ:ARBK) shares gained 11.8% to $4.18 after falling 8% on Friday.
    • MicroStrategy Incorporated (NASDAQ:MSTR) gained 11.4% to $703.40 after Bitcoin rose above $45,000.
    • Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) rose 10.8% to $19.43.
    • MannKind Corporation (NASDAQ:MNKD) gained 9.9% to $4.0001. MannKind sold a 1% royalty in net sales of Tyvaso DPI (Treprostinil) inhalation powder in exchange for up to $200 million, including the purchase price of $150 million and an additional potential milestone payment of up to $50 million.
    • Moderna, Inc. (NASDAQ:MRNA) climbed 9.8% to $109.18 after Openheimer upgraded the stock from Perform to Outperform.
    • Alpha and Omega Semiconductor Limited (NASDAQ:AOSL) gained 8.8% to $28.36. B. Riley Securities analyst Craig Ellis upgraded Alpha & Omega from Neutral to Buy and raised the price target from $28 to $34.
    • Hut 8 Corp. (NASDAQ:HUT) gained 6.3% to $14.19 amid strength in Bitcoin.
    • CleanSpark, Inc. (NASDAQ:CLSK) gained 6.2% to $11.71 amid strength in Bitcoin.
    • Marathon Digital Holdings, Inc. (NASDAQ:MARA) shares jumped 6% to $24.88 amid strength in Bitcoin.
    • Riot Platforms, Inc. (NASDAQ:RIOT) surged 5.3% to $16.29 mid strength in Bitcoin.

    Losers

    • RenovoRx, Inc. (NASDAQ:RNXT) shares tumbled 29.9% to $1.6050.
    • China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) fell 28.8% to $2.8250 after gaining 92% on Friday.
    • Sentage Holdings Inc. (NASDAQ:SNTG) shares fell 28.8% to $3.56 after jumping over 182% on Friday.
    • LumiraDx Limited (NASDAQ:LMDX) fell 28.7% to $0.0459. LumiraDx agreed to sell its point-of-care technology platform to Roche.
    • Corcept Therapeutics Incorporated (NASDAQ:CORT) fell 26.3% to $23.93 after the company announced the Court for the District of New Jersey issued a decision that Teva Pharmaceuticals does not infringe any asserted claims of Corcept's U.S. Patents 10,195,214 and 10,842,800.
    • Anavex Life Sciences Corp. (NASDAQ:AVXL) shares fell 26.2% to $6.88 after the company provided an update on Rett Syndrome program.
    • Mobix Labs, Inc. (NASDAQ:MOBX) fell 25.6% to $2.9895.
    • FLJ Group Limited (NASDAQ:FLJ) shares fell 21% to $1.58 after surging 48% on Friday.
    • Aditxt, Inc. (NASDAQ:ADTX) shares fell 21% to $5.24 after jumping around 38% on Friday.
    • Vertex Energy, Inc. (NASDAQ:VTNR) declined 20.1% to $2.7069 after the company announced it amended its existing term loan agreement, which provides for an incremental $50 million in borrowings to the company.
    • Vast Renewables Limited (NASDAQ:VSTE) fell 17.2% to $4.14.
    • JOYY Inc. (NASDAQ:YY) fell 16.2% to $33.27 after the company announced it received a written notice from an affiliate of Baidu purporting to terminate the Share Purchase Agreement, dated Nov. 16, 2020.
    • GoodRx Holdings, Inc. (NASDAQ:GDRX) dipped 15.5% to $5.66 after B of A Securities downgraded the stock from Buy to Underperform and lowered its price target from $8 to $4.5.
    • China Green Agriculture, Inc. (NYSE:CGA) shares fell 15.2% to $2.57 after jumping over 59% on Friday.
    • KORE Group Holdings, Inc. (NYSE:KORE) shares fell 13.8% to $0.8451 after jumping over 40% on Friday.
    • Aurora Innovation, Inc. (NASDAQ:AUR) fell 13.8% to $3.7605 after the company filed for an $850 million mixed securities shelf offering.
    • ToughBuilt Industries, Inc. (NASDAQ:TBLT) declined 13.5% to $8.86.
    • Bitdeer Technologies Group (NASDAQ:BTDR) fell 12.5% to $8.63.
    • Amprius Technologies, Inc. (NYSE:AMPX) fell 11.5% to $4.68.
    • PureTech Health plc (NASDAQ:PRTC) fell 9.6% to $24.79.
    • Rivian Automotive, Inc. (NASDAQ:RIVN) dipped 9.1% to $21.34 after the company reported delivery and production figures for 2023.
    • Fisker Inc. (NYSE:FSR) fell 7.7% to $1.6141.

     

    Now Read This: Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in January

    Get the next $ADTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADTX
    $AHG
    $ALLO
    $AMPX

    CompanyDatePrice TargetRatingAnalyst
    Strategy Inc
    $MSTR
    3/10/2026$175.00Buy
    B. Riley Securities
    Rivian Automotive Inc.
    $RIVN
    3/10/2026$20.00Hold → Buy
    TD Cowen
    Lyell Immunopharma Inc.
    $LYEL
    3/9/2026$34.00Mkt Outperform
    Citizens
    Rivian Automotive Inc.
    $RIVN
    3/4/2026$14.00Underperform
    BofA Securities
    MARA Holdings Inc.
    $MARA
    2/27/2026Buy → Neutral
    H.C. Wainwright
    MannKind Corporation
    $MNKD
    2/27/2026$3.50Outperform → Sector Perform
    RBC Capital Mkts
    GoodRx Holdings Inc.
    $GDRX
    2/27/2026Overweight → Neutral
    Analyst
    Amprius Technologies Inc.
    $AMPX
    2/23/2026$17.00Buy
    Craig Hallum
    More analyst ratings

    $ADTX
    $AHG
    $ALLO
    $AMPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Strategy Inc with a new price target

    B. Riley Securities initiated coverage of Strategy Inc with a rating of Buy and set a new price target of $175.00

    3/10/26 8:42:16 AM ET
    $MSTR
    Computer Software: Prepackaged Software
    Technology

    Rivian Automotive upgraded by TD Cowen with a new price target

    TD Cowen upgraded Rivian Automotive from Hold to Buy and set a new price target of $20.00

    3/10/26 8:38:01 AM ET
    $RIVN
    Auto Manufacturing
    Industrials

    Citizens initiated coverage on Lyell Immunopharma with a new price target

    Citizens initiated coverage of Lyell Immunopharma with a rating of Mkt Outperform and set a new price target of $34.00

    3/9/26 9:07:38 AM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $AHG
    $ALLO
    $AMPX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RenovoRx Announces $10 Million at Market Private Placement

    Bolstered Cash Position Expected to Capitalize the Company's Momentum Towards Important Milestones, Including Breakeven Operations and Trial Data Oversubscribed Financing Led by Leading Life Science Institutional Investors with Participation from Senior Management and Board Members MOUNTAIN VIEW, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced the execution of definitive securities purchase agreements with institutional investors for an oversubscribed common stock and

    3/18/26 8:35:18 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sensorion Reports Full-Year 2025 Results, Provides Corporate Update and Announces Release of Annual Report

    GJB2-GT (SENS-601) CTA/IND-enabling studies progress, supported by regulatory interactions with FDA and EMA since Q3 2025, and on track for CTA submission in H1 2026 SENS-501 Audiogene trial ongoing; six-month efficacy data expected in Q1 2026 Strengthened balance sheet and shareholder registry via €60m financing in January 2026, including a €20m strategic investment from Sanofi; cash runway extended to end of H1 2027 Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reported its full-year 2025 results, provided a corp

    3/18/26 2:30:00 AM ET
    $LBPH
    $ARNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alpha and Omega Semiconductor Introduces 25V and 80V MOSFETs in State-of-the-Art Packaging that Meets Increasing AI Server Power Demands

    Designed to support high-power density and enhanced thermal performance, new MOSFETs in DFN 3.3x3.3 double-sided cooling source-down packaging feature center gate technology for easier routing on the PCB Alpha and Omega Semiconductor Limited (AOS) (NASDAQ:AOSL), a designer, developer, and global supplier of a broad range of discrete power devices, wide band gap power devices, power management ICs, and modules, today introduced its AONC40202 25V MOSFET and AONC68816 80V MOSFET that are available in state-of-the-art DFN 3.3x3.3 double-sided cooling source-down packaging. Designed to support high power density in Intermediate Bus Converters (IBC) DC-DC applications in AI Servers, the AONC402

    3/17/26 8:00:00 AM ET
    $AOSL
    Semiconductors
    Technology

    $ADTX
    $AHG
    $ALLO
    $AMPX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $330,182 worth of shares (171,034 units at $1.93) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    3/17/26 8:10:19 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Chief Executive Officer Castagna Michael bought $259,000 worth of shares (100,000 units at $2.59), increasing direct ownership by 4% to 2,575,911 units (SEC Form 4)

    4 - MANNKIND CORP (0000899460) (Issuer)

    3/10/26 9:30:02 PM ET
    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Arch Venture Partners Ix, Llc bought $12,499,985 worth of shares (488,090 units at $25.61) (SEC Form 4)

    4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

    3/9/26 4:36:20 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $AHG
    $ALLO
    $AMPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Yang Guang George

    3 - Bitdeer Technologies Group (0001899123) (Issuer)

    3/18/26 9:25:28 PM ET
    $BTDR
    Finance: Consumer Services
    Finance

    SEC Form 3 filed by new insider Trainor-Degirolamo Sheldon

    3 - Bitdeer Technologies Group (0001899123) (Issuer)

    3/18/26 9:24:40 PM ET
    $BTDR
    Finance: Consumer Services
    Finance

    SEC Form 3 filed by new insider Basit Haris Fozan

    3 - Bitdeer Technologies Group (0001899123) (Issuer)

    3/18/26 9:23:52 PM ET
    $BTDR
    Finance: Consumer Services
    Finance

    $ADTX
    $AHG
    $ALLO
    $AMPX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

    For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

    11/30/20 5:12:14 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADTX
    $AHG
    $ALLO
    $AMPX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by SenesTech Inc.

    SCHEDULE 13G/A - SenesTech, Inc. (0001680378) (Subject)

    3/18/26 5:23:43 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    GoodRx Holdings Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - GoodRx Holdings, Inc. (0001809519) (Filer)

    3/18/26 4:59:09 PM ET
    $GDRX
    EDP Services
    Technology

    SEC Form 144 filed by Allogene Therapeutics Inc.

    144 - Allogene Therapeutics, Inc. (0001737287) (Subject)

    3/16/26 8:05:32 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADTX
    $AHG
    $ALLO
    $AMPX
    Leadership Updates

    Live Leadership Updates

    View All

    Sensorion Reports Full-Year 2025 Results, Provides Corporate Update and Announces Release of Annual Report

    GJB2-GT (SENS-601) CTA/IND-enabling studies progress, supported by regulatory interactions with FDA and EMA since Q3 2025, and on track for CTA submission in H1 2026 SENS-501 Audiogene trial ongoing; six-month efficacy data expected in Q1 2026 Strengthened balance sheet and shareholder registry via €60m financing in January 2026, including a €20m strategic investment from Sanofi; cash runway extended to end of H1 2027 Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reported its full-year 2025 results, provided a corp

    3/18/26 2:30:00 AM ET
    $LBPH
    $ARNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

    Patient dosing has commenced in first-of-its-kind Phase 3 head-to-head CAR T-cell 2L randomized controlled clinical trial (PiNACLE-H2H) in patients with large B-cell lymphoma, and the 3L+ pivotal trial (PiNACLE) evaluating ronde-cel is ongoingPhase 1 trial is ongoing for LYL273, an enhanced GCC-targeted CAR T-cell candidate for metastatic colorectal cancer; seven new patients treated without dose-limiting toxicity and including dose escalation to Dose Level 3Smital Shah was appointed Chief Financial and Business Officer in March 2026Second $50 million tranche of $100 million equity private placement closed in March 2026 after achievement of clinical milestone for ronde-celCash of approximate

    3/12/26 4:05:00 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

    Over the past year, RenovoRx has Tripled Commercially Active U.S. Cancer Centers and Centers Requesting Access to RenovoCath, its FDA-Cleared Device Over 700 RenovoCath Procedures Successfully Completed Since FDA Clearance in 2014 Company Appoints Ramtin Agah, MD to the Additional Position of Executive Chairman to Support Continued Clinical Adoption and Commercial Growth MOUNTAIN VIEW, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced continued commercial progress, with

    2/27/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $AHG
    $ALLO
    $AMPX
    Financials

    Live finance-specific insights

    View All

    Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

    Ignite plans to launch a new program in 2026 supporting treatment selection for more than 600,000 people in the United States living with metastatic cancer and limited therapeutic options. Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the acquisition of Ignite Proteomics, LLC ("Ignite"), a commercial-stage precision oncology company focused on addressing a critical challenge in cancer care: optimizing therapy selection. Ignite's functional proteomics platform has demonstrated the ability to identify cancer therapy responses that may not be captured by standard genomic testing alone. Aditxt

    3/13/26 8:15:00 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SenesTech Announces 2025 Financial Results Driven by Strong Growth in E-Commerce

    SURPRISE, Ariz., March 12, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, today announced financial results for the fourth quarter and the full year ended December 31, 2025. 2025 HighlightsRevenue increased by 20% to $2.2 million in 2025 as compared to 2024, driven by strong growth in the Company's overall e-commerce channels despite the impact associated with the Company's transition to directly managing Amazon sales of Evolve® Rat and Evolve Mouse. Excluding this transition-related impact, we estimate re

    3/12/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

    Pivotal, Randomized Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Positions Company at the Forefront of MRD-Guided 1L Consolidation Treatment in Both Academic and Community Cancer Centers, and Advances a Broader Delivery of CAR T at Biologic-Like ScaleInterim Futility Analysis Evaluating MRD Clearance and Early Safety Results Planned for April 2026 Phase 1 RESOLUTION Trial with ALLO-329 in Autoimmune Disease (AID) ALLO-329, a Dual CD19/CD70 CAR, Harnesses the Dagger® Technology to Reduce or Eliminate LymphodepletionRESOLUTION Basket Trial in Rheumatology Enrolling in the Dose Escalation Phase with Proof-of-Co

    3/12/26 4:02:00 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADTX
    $AHG
    $ALLO
    $AMPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by JOYY Inc.

    SC 13G/A - JOYY Inc. (0001530238) (Subject)

    11/14/24 7:58:46 PM ET
    $YY
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by ToughBuilt Industries Inc.

    SC 13G/A - Toughbuilt Industries, Inc (0001668370) (Subject)

    11/14/24 7:29:15 PM ET
    $TBLT
    Industrial Machinery/Components
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:28:08 PM ET
    $SNES
    Agricultural Chemicals
    Industrials